Melanoma Cells News and Research

RSS

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas.

19 Jun 2015

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine.

19 Jun 2015

Researchers find easy way to produce carbon nanoparticles that can carry drugs to targeted tissues

Researchers have found an easy way to produce carbon nanoparticles that are small enough to evade the body's immune system, reflect light in the near-infrared range for easy detection, and carry payloads of pharmaceutical drugs to targeted tissues.

19 Jun 2015

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell.

18 Jun 2015

Presence of collagen in tumor microenvironment can be either good or bad

The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.

21 May 2015

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

Subpopulation of tumor cells make melanoma aggressive

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures.

10 Apr 2015

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.

23 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened.

13 Mar 2015

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Scientists demonstrate the importance of RNA editing in melanoma development

The importance of RNA editing in melanoma has been demonstrated by scientists at The University of Texas MD Anderson Cancer Center. The study revealed that a lack of RNA editing, a process by which information inside RNA molecules is transformed, leads to tumor growth and progression through manipulation of proteins.

17 Feb 2015

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer's spread -- and essentially setting the biological fate of the disease.

15 Feb 2015

Researchers reveal role of epigenetic factors in malignant skin cancer

Melanoma, the most aggressive of all skin cancer strains, is often fatal for patients due to the pronounced formation of metastases. Until now, a melanoma's rampant growth was mainly attributed to genetic causes, such as mutations in certain genes. However, researchers from the University of Zurich now reveal that so-called epigenetic factors play a role in the formation of metastases in malignant skin cancer. This opens up new possibilities for future cancer treatments.

22 Jan 2015

Melanoma Cells News and Research

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Researchers find easy way to produce carbon nanoparticles that can carry drugs to targeted tissues

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Presence of collagen in tumor microenvironment can be either good or bad

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Scientists uncover new pharmaceutical strategy for treating melanoma

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Subpopulation of tumor cells make melanoma aggressive

UQDI reveals that Anisina drug can kill melanoma cells

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Scientists demonstrate the importance of RNA editing in melanoma development

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

Researchers reveal role of epigenetic factors in malignant skin cancer

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News